Susquehanna International Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Susquehanna International Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,560	Closed	-$600K	–	13237
2020 Q4	$600K	Sell	4,560 -362	-7%	-$32K	﹤0.01%	7890
2020 Q3	$249K	Sell	4,922 -35,627	-88%	-$1.6M	﹤0.01%	9078
2020 Q2	$1.93M	Buy	40,549 +34,915	+620%	+$1.62M	﹤0.01%	4565
2020 Q1	$276K	Buy	+5,634	New	+$287K	﹤0.01%	8142
2019 Q4	–	Sell	-23,003	Closed	-$1.14M	–	11070
2019 Q3	$827K	Buy	+23,003	New	+$899K	﹤0.01%	6121
2018 Q4	–	Sell	-11,764	Closed	-$117K	–	10391
2018 Q3	$117K	Buy	+11,764	New	+$193K	﹤0.01%	8542

Susquehanna International Group's EIDX Position: Q1 2021 in Review

Susquehanna International Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 4,560 shares — an estimated $600K sold.

Susquehanna International Group first reported a position in EIDX in Q3 2018 and held it in 6 quarters. The position peaked at $1.93M in Q2 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Susquehanna International Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Susquehanna International Group sold 4,560 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $600K.
Susquehanna International Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 6 quarters.
Susquehanna International Group's Eidos Therapeutics, Inc. Common Stock position peaked at $1.93M in Q2 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.